王一盈

Cooley advised biotechnology company Keymed Biosciences on its HK$3.1 billion (US$400 million) initial public offering on the Hong Kong Stock Exchange. Partners Yiming Liu, Michael Yu and Will Cai led the Cooley team advising Keymed Biosciences on its public debut, which also included Yiying Wang, Xiaoyu Xu, Kaiting Yang, Henry Wang, Bridget Wang and Iris Yang.

Cooley advised Asymchem Laboratories, a contract development manufacturing organization (CDMO) serving the global pharmaceutical industry, on its HK$7.15 billion (US$916 million) initial public offering – marking the largest healthcare IPO in Hong Kong this year – of 18,415,400 H shares, which now trade on the Hong Kong Stock Exchange. Partners Yiming Liu and Michael Yu led the Cooley team advising Asymchem.

Cooley advised Asymchem, a Chinese-based contract development and manufacturing company serving the global pharmaceutical and biotech industry, on its definitive agreement to acquire Snapdragon Chemistry, a US-based chemical technology company. Partner Yiming Liu led the Cooley team.

As a result of the transaction, Asymchem will significantly expand its footprint in the US, offering customers a seamless path from preclinical process R&D through commercial current good manufacturing practice (cGMP) production. Snapdragon will operate as a stand-alone Asymchem division, and continue with its ongoing lab and manufacturing facility expansion for additional capacity to support larger, pilot-scale manufacturing in Waltham, Massachusetts.

"We believe continuous flow manufacturing is a revolutionary technology and represents the future of pharmaceutical production, not only generating advantages to process safety and cost, but also bringing tremendous environmental benefits," Hao Hong, chairman and CEO of Asymchem, said in a news release. "Asymchem has been deeply committed to flow chemistry technology development and its application expansion in the pharmaceutical industry for more than a decade. We are excited that this strategic acquisition will further strengthen our capabilities in continuous manufacturing, as well as broadening our service scope and client pool."

Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$350.9 million placement of new shares under general mandate.